Biogen (NASDAQ:BIIB) Price Target Cut to $200.00
Biogen (NASDAQ:BIIB – Get Free Report) had its price target lowered by equities research analysts at Barclays from $215.00 to $200.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s target price points to a potential downside of 1.15% from the […]